Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Conduit Pharmaceuticals ( (CDT) ).
On December 8, 2025, CDT Equity Inc. entered into a Sale and Purchase Agreement with Corvus Capital Limited for the sale of its subsidiary, Conduit Pharmaceuticals Limited (CPL), which had been involved in ongoing litigation. The transaction involved the issuance of CDT Shares and Pre-Funded Warrants to Corvus, a subsidiary of the company’s CEO, for a settlement amount of $7,000,000. This strategic move was aimed at simplifying CDT Equity’s organizational structure and transferring potential litigation liabilities. The agreement also includes provisions for stockholder approval and the filing of a resale registration statement to facilitate the resale of the issued shares and warrants.
More about Conduit Pharmaceuticals
Average Trading Volume: 779,556
Technical Sentiment Signal: Sell
Current Market Cap: $3.24M
For an in-depth examination of CDT stock, go to TipRanks’ Overview page.